$1.19
6.25%
Nasdaq, Aug 22, 10:02 pm CET
ISIN
US0197701065
Symbol
ALLO

Allogene Therapeutics, Inc. Stock price

$1.19
-0.23 16.20% 1M
-0.95 44.39% 6M
-0.94 44.13% YTD
-1.40 54.05% 1Y
-13.19 91.72% 3Y
-33.50 96.57% 5Y
-23.81 95.24% 10Y
-23.81 95.24% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.07 6.25%
ISIN
US0197701065
Symbol
ALLO
Industry

Key metrics

Basic
Market capitalization
$264.0m
Enterprise Value
$-9.1m
Net debt
positive
Cash
$273.1m
Shares outstanding
220.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 23,300.0
EV/Sales
- | negative
EV/FCF
0.1
P/B
0.8
Financial Health
Equity Ratio
76.9%
Return on Equity
-61.0%
ROCE
-55.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $11.3k
EBITDA
$-228.5m | $-227.8m
EBIT
$-241.2m | $-245.0m
Net Income
$-236.9m | $-222.4m
Free Cash Flow
$-173.6m
Growth (TTM | estimate)
Revenue
-100.0% | -43.5%
EBITDA
54.2% | 6.6%
EBIT
53.0% | 4.8%
Net Income
54.4% | 13.7%
Free Cash Flow
24.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -2,010,426.0%
EBIT
-
Net
- | -1,962,386.6%
Free Cash Flow
-
More
EPS
$-1.1
FCF per Share
$-0.8
Short interest
13.5%
Employees
228
Rev per Employee
$0.0
Show more

Is Allogene Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Allogene Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Allogene Therapeutics, Inc. forecast:

17x Buy
85%
3x Hold
15%

Analyst Opinions

20 Analysts have issued a Allogene Therapeutics, Inc. forecast:

Buy
85%
Hold
15%

Financial data from Allogene Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
50% 50%
-
- Research and Development Expense 180 180
54% 54%
-
-229 -229
54% 54%
-
- Depreciation and Amortization 13 13
11% 11%
-
EBIT (Operating Income) EBIT -241 -241
53% 53%
-
Net Profit -237 -237
54% 54%
-

In millions USD.

Don't miss a Thing! We will send you all news about Allogene Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Allogene Therapeutics, Inc. Stock News

Positive
Seeking Alpha
11 days ago
I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains solid, with over $300 million in liquidity, sufficient to reach key data catalysts through 2027 despite brisk cash burn. The upcoming ALPHA3 futility analysis in 1H 2026 is a critical catalyst; po...
Neutral
Seeking Alpha
11 days ago
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David D. Chang - Co-Founder, President, CEO & Director Geoffrey M.
Neutral
GlobeNewsWire
12 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2025.
More Allogene Therapeutics, Inc. News

Company Profile

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO David Chang
Employees 228
Founded 2017
Website allogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today